{"id":766611,"date":"2023-06-28T08:04:54","date_gmt":"2023-06-28T12:04:54","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-received-a-1-mm-loan-forgiveness-and-6-month-payment-deferral-from-the-ct-decd\/"},"modified":"2023-06-28T08:04:54","modified_gmt":"2023-06-28T12:04:54","slug":"aspira-womens-health-inc-received-a-1-mm-loan-forgiveness-and-6-month-payment-deferral-from-the-ct-decd","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-received-a-1-mm-loan-forgiveness-and-6-month-payment-deferral-from-the-ct-decd\/","title":{"rendered":"Aspira Women\u2019s Health, Inc. Received a $1 MM Loan Forgiveness and 6-Month Payment Deferral from the CT DECD"},"content":{"rendered":"
\n

AUSTIN, Texas, June 28, 2023 (GLOBE NEWSWIRE) — Aspira Women\u2019s Health, Inc. (\u201cAspira\u201d or the \u201cCompany\u201d) (Nasdaq: AWH), a bio-analytical based women\u2019s health company focused on the development of gynecologic disease diagnostic tools, today announced that the Connecticut Department of Economic and Community Development (\u201cDECD\u201d) has determined that Aspira satisfied all job creation and retention requirements under the loan agreement entered into by the Company and DECD in 2016. As a result, Aspira is entitled to a credit of $1,000,000 towards its outstanding loan balance. Following the loan forgiveness, the Company\u2019s total outstanding debt obligations will be approximately $1.6 million. In a separate agreement, the DECD agreed to defer all principal and interest payments due under all outstanding loan agreements until December 1, 2023.<\/p>\n

As a result of the loan forgiveness and deferrals, the Company expects cash outflows for the year ending December 31, 2023, to be reduced by $247,000.<\/p>\n

\n About\u00a0Aspira\u00a0Women\u2019s\u00a0Health\u00a0Inc.\u00a0<\/strong>
\n
\n Aspira Women\u2019s Health Inc.<\/a> is transforming women\u2019s gynecological health with the discovery, development, and commercialization of innovative testing options for women of all races and ethnicities, starting with ovarian cancer.\u00a0\u00a0\u00a0<\/p>\n

Our ovarian cancer risk assessment portfolio is marketed to healthcare providers as OvaSuiteSM<\/sup>. OvaWatchSM<\/sup>\u00a0is a non-invasive, blood-based test intended for use in the initial clinical assessment of ovarian cancer risk in women with benign or indeterminate adnexal masses for which surgical intervention may be either premature or unnecessary. With a negative predictive value (NPV) of 99%, OvaWatch allows physicians to confidently rule out ovarian cancer malignancy and choose the appropriate clinical management for the right patient at the right time. Ova1Plus\u00ae<\/sup>\u00a0combines our FDA-cleared products, Ova1\u00ae<\/sup>\u00a0and Overa\u00ae<\/sup>, to detect risk of ovarian malignancy in women with adnexal masses planned for surgery.\u00a0\u00a0\u00a0<\/p>\n

EndoCheck\u2122, Aspira\u2019s first-of-its-kind non-invasive diagnostic test for endometriosis, is currently in development. Visit our website for more information at\u00a0www.aspirawh.com<\/a>.\u00a0\u00a0<\/p>\n

\n Forward-Looking\u00a0Statements <\/strong>
\n
This press release contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve a number of risks and uncertainties. Words such as \u201cmay,\u201d \u201cexpects,\u201d \u201cintends,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cplans,\u201d \u201cseeks,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccontinue,\u201d \u201cwill,\u201d \u201cpotential,\u201d \u201cprojects\u201d and similar expressions are intended to identify forward-looking statements. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties, and assumptions, including those described in the section entitled \u201cRisk Factors\u201d in Aspira\u2019s Annual Report on Form 10-K for the year ended December 31, 2022, and as supplemented in Aspira\u2019s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023. These risks include, but are not limited to: our ability to continue as a going concern; our ability to comply with Nasdaq\u2019s continued listing requirements; impacts resulting from potential changes to coverage of Ova1 through our Medicare Administrative Carrier for Ova1; impacts resulting from or relating to the COVID-19 pandemic and actions taken to contain it; anticipated use of capital and its effects; our ability to increase the volume of our product sales; failures by third-party payers to reimburse for our products and services or changes to reimbursement rates; our ability to continue developing existing technologies and to develop, protect and promote our proprietary technologies; plans to develop and perform laboratory developed tests; our ability to comply with Food and Drug Administration (\u201cFDA\u201d) regulations that relate to our products and to obtain any FDA clearance or approval required to develop and commercialize medical devices; our ability to develop and commercialize additional diagnostic products and achieve market acceptance with respect to these products; our ability to compete successfully; our ability to obtain any regulatory approval required for our future diagnostic products; or our suppliers\u2019 ability to comply with FDA requirements for production, marketing and post-market monitoring of our products; our ability to maintain sufficient or acceptable supplies of immunoassay kits from our suppliers; in the event that we succeed in commercializing our products outside the United States, the political, economic and other conditions affecting other countries; changes in healthcare policy; our ability to comply with the additional laws and regulations that apply to us in connection with the operation of Aspira Labs; our ability to use our net operating loss carryforwards; our ability to use intellectual property; our ability to successfully defend our proprietary technology against third parties; our ability to obtain licenses in the event a third party successfully asserts proprietary rights; the liquidity and trading volume of our common stock; the concentration of ownership of our common stock; our ability to retain key employees; our ability to secure additional capital on acceptable terms to execute our business plan; business interruptions; the effectiveness and availability of our information systems; our ability to integrate and achieve anticipated results from any acquisitions or strategic alliances; future litigation against us, including infringement of intellectual property and product liability exposure; and additional costs that may be required to make further improvements to our laboratory operations. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Aspira presently does not know, or that Aspira currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Aspira\u2019s expectations, plans, or forecasts of future events and views as of the date of this press release. Subsequent events and developments may cause the Company\u2019s assessments to change. However, while Aspira may elect to update these forward-looking statements at some point in the future, Aspira expressly disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Aspira\u2019s assessments of any date after the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.<\/p>\n

\n
\n Investor Relations Contact:<\/em>
\n <\/strong>
\n
Monique Kosse\u00a0
Managing Director
LifeSci Advisors, LLC
Tel: 212-915-3820
monique@lifesciadvisors.com<\/strong><\/a><\/p>\n

\n
\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

AUSTIN, Texas, June 28, 2023 (GLOBE NEWSWIRE) — Aspira Women\u2019s Health, Inc. (\u201cAspira\u201d or the \u201cCompany\u201d) (Nasdaq: AWH), a bio-analytical based women\u2019s health company focused on the development of gynecologic disease diagnostic tools, today announced that the Connecticut Department of Economic and Community Development (\u201cDECD\u201d) has determined that Aspira satisfied all job creation and retention requirements under the loan agreement entered into by the Company and DECD in 2016. As a result, Aspira is entitled to a credit of $1,000,000 towards its outstanding loan balance. Following the loan forgiveness, the Company\u2019s total outstanding debt obligations will be approximately $1.6 million. In a separate agreement, the DECD agreed to defer all principal and interest payments due under all outstanding loan agreements … <\/p>\n

Continue reading “Aspira Women\u2019s Health, Inc. Received a $1 MM Loan Forgiveness and 6-Month Payment Deferral from the CT DECD”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-766611","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAspira Women\u2019s Health, Inc. Received a $1 MM Loan Forgiveness and 6-Month Payment Deferral from the CT DECD - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-received-a-1-mm-loan-forgiveness-and-6-month-payment-deferral-from-the-ct-decd\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aspira Women\u2019s Health, Inc. Received a $1 MM Loan Forgiveness and 6-Month Payment Deferral from the CT DECD - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"AUSTIN, Texas, June 28, 2023 (GLOBE NEWSWIRE) — Aspira Women\u2019s Health, Inc. (\u201cAspira\u201d or the \u201cCompany\u201d) (Nasdaq: AWH), a bio-analytical based women\u2019s health company focused on the development of gynecologic disease diagnostic tools, today announced that the Connecticut Department of Economic and Community Development (\u201cDECD\u201d) has determined that Aspira satisfied all job creation and retention requirements under the loan agreement entered into by the Company and DECD in 2016. As a result, Aspira is entitled to a credit of $1,000,000 towards its outstanding loan balance. Following the loan forgiveness, the Company\u2019s total outstanding debt obligations will be approximately $1.6 million. In a separate agreement, the DECD agreed to defer all principal and interest payments due under all outstanding loan agreements … Continue reading "Aspira Women\u2019s Health, Inc. Received a $1 MM Loan Forgiveness and 6-Month Payment Deferral from the CT DECD"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-received-a-1-mm-loan-forgiveness-and-6-month-payment-deferral-from-the-ct-decd\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-28T12:04:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2NTc1NSM1NjY4Mjk5IzUwMDA0NTYzNw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-received-a-1-mm-loan-forgiveness-and-6-month-payment-deferral-from-the-ct-decd\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-received-a-1-mm-loan-forgiveness-and-6-month-payment-deferral-from-the-ct-decd\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Aspira Women\u2019s Health, Inc. Received a $1 MM Loan Forgiveness and 6-Month Payment Deferral from the CT DECD\",\"datePublished\":\"2023-06-28T12:04:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-received-a-1-mm-loan-forgiveness-and-6-month-payment-deferral-from-the-ct-decd\\\/\"},\"wordCount\":1002,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-received-a-1-mm-loan-forgiveness-and-6-month-payment-deferral-from-the-ct-decd\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2NTc1NSM1NjY4Mjk5IzUwMDA0NTYzNw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-received-a-1-mm-loan-forgiveness-and-6-month-payment-deferral-from-the-ct-decd\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-received-a-1-mm-loan-forgiveness-and-6-month-payment-deferral-from-the-ct-decd\\\/\",\"name\":\"Aspira Women\u2019s Health, Inc. Received a $1 MM Loan Forgiveness and 6-Month Payment Deferral from the CT DECD - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-received-a-1-mm-loan-forgiveness-and-6-month-payment-deferral-from-the-ct-decd\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-received-a-1-mm-loan-forgiveness-and-6-month-payment-deferral-from-the-ct-decd\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2NTc1NSM1NjY4Mjk5IzUwMDA0NTYzNw==\",\"datePublished\":\"2023-06-28T12:04:54+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-received-a-1-mm-loan-forgiveness-and-6-month-payment-deferral-from-the-ct-decd\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-received-a-1-mm-loan-forgiveness-and-6-month-payment-deferral-from-the-ct-decd\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-received-a-1-mm-loan-forgiveness-and-6-month-payment-deferral-from-the-ct-decd\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2NTc1NSM1NjY4Mjk5IzUwMDA0NTYzNw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2NTc1NSM1NjY4Mjk5IzUwMDA0NTYzNw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-received-a-1-mm-loan-forgiveness-and-6-month-payment-deferral-from-the-ct-decd\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aspira Women\u2019s Health, Inc. Received a $1 MM Loan Forgiveness and 6-Month Payment Deferral from the CT DECD\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aspira Women\u2019s Health, Inc. Received a $1 MM Loan Forgiveness and 6-Month Payment Deferral from the CT DECD - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-received-a-1-mm-loan-forgiveness-and-6-month-payment-deferral-from-the-ct-decd\/","og_locale":"en_US","og_type":"article","og_title":"Aspira Women\u2019s Health, Inc. Received a $1 MM Loan Forgiveness and 6-Month Payment Deferral from the CT DECD - Market Newsdesk","og_description":"AUSTIN, Texas, June 28, 2023 (GLOBE NEWSWIRE) — Aspira Women\u2019s Health, Inc. (\u201cAspira\u201d or the \u201cCompany\u201d) (Nasdaq: AWH), a bio-analytical based women\u2019s health company focused on the development of gynecologic disease diagnostic tools, today announced that the Connecticut Department of Economic and Community Development (\u201cDECD\u201d) has determined that Aspira satisfied all job creation and retention requirements under the loan agreement entered into by the Company and DECD in 2016. As a result, Aspira is entitled to a credit of $1,000,000 towards its outstanding loan balance. Following the loan forgiveness, the Company\u2019s total outstanding debt obligations will be approximately $1.6 million. In a separate agreement, the DECD agreed to defer all principal and interest payments due under all outstanding loan agreements … Continue reading \"Aspira Women\u2019s Health, Inc. Received a $1 MM Loan Forgiveness and 6-Month Payment Deferral from the CT DECD\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-received-a-1-mm-loan-forgiveness-and-6-month-payment-deferral-from-the-ct-decd\/","og_site_name":"Market Newsdesk","article_published_time":"2023-06-28T12:04:54+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2NTc1NSM1NjY4Mjk5IzUwMDA0NTYzNw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-received-a-1-mm-loan-forgiveness-and-6-month-payment-deferral-from-the-ct-decd\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-received-a-1-mm-loan-forgiveness-and-6-month-payment-deferral-from-the-ct-decd\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Aspira Women\u2019s Health, Inc. Received a $1 MM Loan Forgiveness and 6-Month Payment Deferral from the CT DECD","datePublished":"2023-06-28T12:04:54+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-received-a-1-mm-loan-forgiveness-and-6-month-payment-deferral-from-the-ct-decd\/"},"wordCount":1002,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-received-a-1-mm-loan-forgiveness-and-6-month-payment-deferral-from-the-ct-decd\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2NTc1NSM1NjY4Mjk5IzUwMDA0NTYzNw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-received-a-1-mm-loan-forgiveness-and-6-month-payment-deferral-from-the-ct-decd\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-received-a-1-mm-loan-forgiveness-and-6-month-payment-deferral-from-the-ct-decd\/","name":"Aspira Women\u2019s Health, Inc. Received a $1 MM Loan Forgiveness and 6-Month Payment Deferral from the CT DECD - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-received-a-1-mm-loan-forgiveness-and-6-month-payment-deferral-from-the-ct-decd\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-received-a-1-mm-loan-forgiveness-and-6-month-payment-deferral-from-the-ct-decd\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2NTc1NSM1NjY4Mjk5IzUwMDA0NTYzNw==","datePublished":"2023-06-28T12:04:54+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-received-a-1-mm-loan-forgiveness-and-6-month-payment-deferral-from-the-ct-decd\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-received-a-1-mm-loan-forgiveness-and-6-month-payment-deferral-from-the-ct-decd\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-received-a-1-mm-loan-forgiveness-and-6-month-payment-deferral-from-the-ct-decd\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2NTc1NSM1NjY4Mjk5IzUwMDA0NTYzNw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2NTc1NSM1NjY4Mjk5IzUwMDA0NTYzNw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-received-a-1-mm-loan-forgiveness-and-6-month-payment-deferral-from-the-ct-decd\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Aspira Women\u2019s Health, Inc. Received a $1 MM Loan Forgiveness and 6-Month Payment Deferral from the CT DECD"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/766611","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=766611"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/766611\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=766611"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=766611"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=766611"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}